The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of United Therapeutics' 2013 cardiovasular sales performance.
Keeping this trend, United Therapeutics has sold a PRV to AbbVie for a headline value of $350m. ... 408. United Therapeutics. AbbVie. Received on approval of Unituxin for neuroblastoma.
Bayer's Adempas (riociguat) and United Therapeutics Orenitram, an oral formulation of the long-standing injectable PAH treatment Remodulin (treprostinil).
Gilead Sciences bought one from Canada's Knight Therapeutics last year that was awarded by the FDA in return for developing a drug for a neglected tropical disease. ... A paediatric PRV awarded to United Therapeutics following FDA approval for its
pulmonary and orphan diseases, served at United Therapeutics.
United Therapeutics’ Unituxin approved for neuroblastoma. . United Therapeutics' Unituxin has become the first-ever therapy approved in the US for neuroblastoma, a rare form of cancer that most commonly occurs in ... according to United Therapeutics'
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...